Search
Gemcitabine
go.drugbank.com/drugs/DB00441ApprovedInvestigationalIt was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. … [L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.
Products: GEMZAR 1gm POWDER FOR SOLUTION FOR INFUSION, GEMZAR 200mg Powder for Solution for InfusionSomatotropin
go.drugbank.com/drugs/DB00052ApprovedInvestigationalIt has an identical primary protein structure to endogenous human growth hormone.[A228188] Recombinant HGH has been commercially available since 1985 after its development by Genentech. … [Somatrem] was the first available recombinant HGH and was largely replaced by somatropin, another form of recombinant HGH.
Products: ZOMACTON Powder and Solvent for Solution for Injection 10mg, ZOMACTON Powder and Solvent for Solution for Injection 4 mgBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationalMRD) greater than or equal to 0.1% in adults and children. … [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]
Categories: Bispecific CD19-directed CD3-directed T Cell EngagerProducts: BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL, BLINCYTO (Blinatumomab) for injection 35 mcg/vialTripelennamine
go.drugbank.com/drugs/DB00792ApprovedVet approvedA histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. … Tripelennamine is administered by various routes, including topically.
Categories: Antihistamines for Systemic Use, Antihistamines for Topical UseProducts: Bug Bite BalmTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigationalTreosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation. … [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]
Products: Treosulfan for Injection, ALLOPRE 5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADETChlorhexidine
go.drugbank.com/drugs/DB00878ApprovedInvestigationalVet approvedWithdrawn[L11572] The FDA withdrew its approval for the use of chlorhexidine gluconate topical tincture 0.5%, due to a significant number of reports concerning chemical and thermal burns associated with the use … [L11518,L11512,A190453] Chlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s[A190474] and was introduced to the US in the 1970s.
Mixtures: KLOROBEN FORT 3 MG/ML+ 2 MG/ML GARGARA, 200 ML, KLOROBEN FORT 3 MG/ML+ 2 MG/ML ORAL SPREY, 40 MLCategories: Antiinfectives and Antiseptics for Local Oral Treatment, Compounds used in a research, industrial, or household settingIbandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. … Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].
Mixtures: İBAMIN D3 150 MG/2800 IU GRANÜL İÇEREN SAŞE ,3 SAŞECategories: Drugs for Treatment of Bone DiseasesRomiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalInterestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.
Products: ROMIPLATE POWDER FOR SOLUTION FOR INJECTION 250 ?g/vial, NPLATE 250 MCG ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADETEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Products: Padcev 30mg Powder for Concentrate for Solution for Infusion, Padcev 20mg Powder for Concentrate for Solution for InfusionDecitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.
Products: DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion, Redtibin (Decitabine) Powder for Injection 50mg/vial